Intended for healthcare professionals

CCBYNC Open access

Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials

BMJ 2012; 345 doi: (Published 10 August 2012) Cite this as: BMJ 2012;345:e5170
  1. Sripal Bangalore, director of research, assistant professor of medicine1,
  2. Sunil Kumar, fellow in cardiovascular medicine2,
  3. Mario Fusaro, resident in internal medicine1,
  4. Nicholas Amoroso, resident in internal medicine1,
  5. Ajay J Kirtane, assistant professor of clinical medicine3,
  6. Robert A Byrne, director, imaging core laboratory7,
  7. David O Williams, professor of medicine4,
  8. James Slater, professor of medicine1,
  9. Donald E Cutlip, professor of medicine56,
  10. Frederick Feit, professor of medicine1
  1. 1New York University School of Medicine, New York, NY 10016, US
  2. 2University of Nebraska, Omaha, Nebraska, NY
  3. 3Columbia University Medical Center, New York Presbyterian Hospital, New York, NY
  4. 4Brigham and Women’s Hospital, Boston, MA, US
  5. 5Beth Israel Deaconess Medical Center, Boston, MA
  6. 6Harvard Clinical Research Institute, Boston, MA
  7. 7Deutsches Herzzentrum, Technische Universität, University of Munich, Munich, Germany
  1. Correspondence to: S Bangalore sripalbangalore{at}
  • Accepted 18 July 2012


Objectives To evaluate the efficacy and safety of currently used drug eluting stents compared with each other and compared with bare metal stents in patients with diabetes.

Design Mixed treatment comparison meta-analysis.

Data sources and study selection PubMed, Embase, and CENTRAL were searched for randomised clinical trials, until April 2012, of four durable polymer drug eluting stents (sirolimus eluting stents, paclitaxel eluting stents, everolimus eluting stents, and zotarolimus eluting stents) compared with each other or with bare metal stents for the treatment of de novo coronary lesions and enrolling at least 50 patients with diabetes.

Primary outcomes Efficacy (target vessel revascularisation) and safety (death, myocardial infarction, stent thrombosis).

Results From 42 trials with 22 844 patient years of follow-up, when compared with bare metal stents (reference rate ratio 1) all of the currently used drug eluting stents were associated with a significant reduction in target vessel revascularisation (37% to 69%), though the efficacy varied with the type of stent (everolimus eluting stents∼sirolimus eluting stents>paclitaxel eluting stents∼zotarolimus eluting stent>bare metal stents). There was about an 87% probability that everolimus eluting stents were the most efficacious compared with all others, though there were limited usable data for the zotarolimus eluting Resolute stent in patients with diabetes. Moreover, there was no increased risk of any safety outcome (including very late stent thrombosis) with any drug eluting stents compared with bare metal stents. There was about a 62% probability that the everolimus eluting stent was the safest stent for the outcome of “any” stent thrombosis.

Conclusions Among patients with diabetes treated with coronary stents all currently available drug eluting stents were efficacious without compromising safety compared with bare metal stents. There were relative differences among the drug eluting stents, such that the everolimus eluting stent was the most efficacious and safe.


  • Contributors: SB had the original concept and designed the study; acquired, analysed, and interpreted the data; and drafted the paper. SK, MF, and NA also acquired data. All authors critically revised the manuscript for important intellectual content. SB was responsible for statistical analysis, supervised the study, and is guarantor.

  • Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests: All authors have completed the ICMJE uniform disclosure form at (available on request from the corresponding author) and declare that SB is on the advisory boards of Boehringer Ingelheim and Daiichi Sankyo and DEC was prinicpal investigator on the Medtronic EDUCATE trial.

  • Ethical approval: Not required.

  • Data sharing: No additional data available.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and

View Full Text